Raymond James & Associates’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $201K | Buy |
118,197
+8,430
| +8% | +$14.3K | ﹤0.01% | 3608 |
|
|
2024
Q2 | $150K | Buy |
109,767
+23,161
| +27% | +$31.7K | ﹤0.01% | 3630 |
|
|
2024
Q1 | $325K | Buy |
86,606
+19,213
| +29% | +$72K | ﹤0.01% | 3307 |
|
|
2023
Q4 | $661K | Buy |
67,393
+12,373
| +22% | +$121K | ﹤0.01% | 2767 |
|
|
2023
Q3 | $459K | Sell |
55,020
-18,726
| -25% | -$156K | ﹤0.01% | 2935 |
|
|
2023
Q2 | $981K | Sell |
73,746
-4,636
| -6% | -$61.7K | ﹤0.01% | 2471 |
|
|
2023
Q1 | $908K | Sell |
78,382
-7,078
| -8% | -$82K | ﹤0.01% | 2495 |
|
|
2022
Q4 | $699K | Sell |
85,460
-9,630
| -10% | -$78.8K | ﹤0.01% | 2643 |
|
|
2022
Q3 | $552K | Buy |
95,090
+1,365
| +1% | +$7.92K | ﹤0.01% | 2787 |
|
|
2022
Q2 | $414K | Sell |
93,725
-17,961
| -16% | -$79.3K | ﹤0.01% | 3013 |
|
|
2022
Q1 | $1.02M | Buy |
111,686
+813
| +0.7% | +$7.4K | ﹤0.01% | 2574 |
|
|
2021
Q4 | $2.27M | Sell |
110,873
-22,300
| -17% | -$456K | ﹤0.01% | 2085 |
|
|
2021
Q3 | $3.4M | Buy |
133,173
+3,214
| +2% | +$82.1K | ﹤0.01% | 1742 |
|
|
2021
Q2 | $4.55M | Sell |
129,959
-19,610
| -13% | -$686K | ﹤0.01% | 1548 |
|
|
2021
Q1 | $4.98M | Buy |
149,569
+46,782
| +46% | +$1.56M | 0.01% | 1426 |
|
|
2020
Q4 | $2.67M | Sell |
102,787
-20,018
| -16% | -$519K | ﹤0.01% | 1715 |
|
|
2020
Q3 | $1.21M | Buy |
122,805
+74,394
| +154% | +$734K | ﹤0.01% | 2060 |
|
|
2020
Q2 | $167K | Buy |
+48,411
| New | +$167K | ﹤0.01% | 3156 |
|
|
2019
Q4 | – | Sell |
-12,000
| Closed | -$62K | – | 3594 |
|
|
2019
Q3 | $62K | Hold |
12,000
| – | – | ﹤0.01% | 3408 |
|
|
2019
Q2 | $73K | Hold |
12,000
| – | – | ﹤0.01% | 3403 |
|
|
2019
Q1 | $87K | Buy |
+12,000
| New | +$87K | ﹤0.01% | 3380 |
|